Iterum Therapeutics
Yahoo Finance • last year
Iterum Therapeutics Reports Third Quarter 2023 Financial Results
-- Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – --Resubmission of NDA for uUTI Expected in Q2 2024-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum... Full story
Yahoo Finance • last year
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infection... Full story
Yahoo Finance • last year
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
– Topline Data Expected in Early Q1 2024 – – NDA Resubmission Expected in Q2 2024 – DUBLIN, Ireland and CHICAGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company... Full story
Yahoo Finance • last year
Iterum Therapeutics to Present Data at IDWeek 2023
DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infection... Full story
Yahoo Finance • last year
Iterum Therapeutics to Present Data at ASM Microbe 2023
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infection... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics Reports First Quarter 2023 Financial Results
--Registration Trial for uUTI Ongoing and On Track-- --Cash Runway until Mid-2024-- DUBLIN, Ireland and CHICAGO, May 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials
DUBLIN, Ireland and CHICAGO, April 20, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infectio... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infectio... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics Reports Employment Inducement Grant
DUBLIN, Ireland and CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum Therapeutics”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
DUBLIN, Ireland and CHICAGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to t... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics Reports Third Quarter 2022 Financial Results
--Patient Enrollment in Registration Trial for uUTI Underway-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on November 10, 2022
DUBLIN, Ireland and CHICAGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infection... Full story
Yahoo Finance • 2 years ago
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
-- NDA resubmission expected in Second Half of 2024, if successful-- --Oral sulopenem, if approved, could be the first antibiotic approved for uncomplicated urinary tract infections in over 25 years-- DUBLIN, Ireland and CHICAGO, Oct. 2... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infectio... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split
Iterum Therapeutics plc DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antib... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics Reports Second Quarter 2022 Financial Results
--Enrollment in Registration Trial for uUTI to Begin Q4 2022-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA
--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical Trial Expected to Begin Enrollment in Q4 2022-- DUBLIN, Ireland and CHICAGO, July 11, 2022 (G... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland and CHICAGO, July 06, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infecti... Full story
Yahoo Finance • 3 years ago
Iterum Therapeutics Provides Regulatory Update
DUBLIN, Ireland and CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infectio... Full story
Yahoo Finance • 3 years ago
Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
DUBLIN, Ireland and CHICAGO, April 25, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infectio... Full story
